# Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker

> **NCT01945606** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 11 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Placebo (treatment 1)
- **DRUG:** BAY1067197 (treatment 2)

## Key facts

- **NCT ID:** NCT01945606
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-29
- **Primary completion:** 2014-09-09
- **Final completion:** 2015-03-17
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01945606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01945606, "Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01945606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*